PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2024 Unbound Medicine, Inc. All rights reserved